Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K. Yoshimura A, et al. Among authors: goto y. Cancer Sci. 2023 Feb;114(2):606-618. doi: 10.1111/cas.15608. Epub 2022 Nov 11. Cancer Sci. 2023. PMID: 36169649 Free PMC article.
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Nakao A, et al. Among authors: goto y. Oncologist. 2019 May;24(5):593-e170. doi: 10.1634/theoncologist.2019-0003. Epub 2019 Jan 16. Oncologist. 2019. PMID: 30651400 Free PMC article. Clinical Trial.
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, Ishizuka T, Takeda T, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Nakao A, et al. Among authors: goto y. J Clin Med. 2020 Jun 5;9(6):1762. doi: 10.3390/jcm9061762. J Clin Med. 2020. PMID: 32517152 Free PMC article.
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: goto y. Oncoimmunology. 2021 Jul 8;10(1):1950411. doi: 10.1080/2162402X.2021.1950411. eCollection 2021. Oncoimmunology. 2021. PMID: 34290909 Free PMC article.
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: goto y. Lung Cancer. 2021 Nov;161:26-33. doi: 10.1016/j.lungcan.2021.08.015. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34500218
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: goto y. J Cancer Res Clin Oncol. 2022 Sep;148(9):2437-2446. doi: 10.1007/s00432-021-03782-5. Epub 2021 Sep 12. J Cancer Res Clin Oncol. 2022. PMID: 34510271
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study.
Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, Shiotsu S, Kunimasa K, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Kenmotsu H, Takahashi T, Takayama K. Yoshimura A, et al. Among authors: goto y. Transl Lung Cancer Res. 2021 Aug;10(8):3582-3593. doi: 10.21037/tlcr-21-461. Transl Lung Cancer Res. 2021. PMID: 34584858 Free PMC article.
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Nakamura R, et al. Among authors: goto y. J Cancer Res Clin Oncol. 2022 Nov;148(11):2985-2994. doi: 10.1007/s00432-021-03866-2. Epub 2021 Nov 26. J Cancer Res Clin Oncol. 2022. PMID: 34825950
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, Hibino M, Tani N, Takeda T, Yamaguchi H, Tachibana Y, Takumi C, Hiraoka N, Takeshita M, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Yamada T, Takayama K. Tanaka S, et al. Among authors: goto y. Diagnostics (Basel). 2022 Feb 6;12(2):423. doi: 10.3390/diagnostics12020423. Diagnostics (Basel). 2022. PMID: 35204513 Free PMC article.
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC.
Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: goto y. JTO Clin Res Rep. 2022 Aug 6;3(9):100388. doi: 10.1016/j.jtocrr.2022.100388. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082280 Free PMC article.
4,530 results